New drug may shield transplant patients from deadly immune attack
NCT ID NCT07381114
First seen Feb 02, 2026 · Last updated May 15, 2026 · Updated 9 times
Summary
This study tests whether the drug ivarmacitinib can prevent acute graft-versus-host disease (aGVHD) in 32 people with blood cancers receiving a stem cell transplant from a half-matched donor. aGVHD occurs when donor immune cells attack the patient's body. The study will measure how many patients develop aGVHD, infections, and other complications over one year. The goal is to improve recovery and survival after transplant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AGVHD are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.